Costa rica launches registry to track eczema patients on advanced drugs
NCT ID NCT07448363
First seen Mar 09, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study will follow 50 Costa Rican adults with moderate-to-severe atopic dermatitis (eczema) who are already receiving advanced treatments like dupilumab or JAK inhibitors as part of their routine care. Researchers will collect data from regular doctor visits to see how symptoms, quality of life, and treatment patterns change over time. The goal is to better understand how these therapies work in real-world settings, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caja Costarricense del Seguro Social
San José, Provincia de San José, 40901, Costa Rica
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.